{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:35:01Z","timestamp":1763728501397,"version":"3.41.2"},"reference-count":35,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Immunity Inflam &amp;amp; Disease"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Ankylosing spondylitis (AS) is a condition that is treated with nonsteroidal anti\u2010inflammatory drugs and biological drugs such as anti tumor necrosis factor alpha (TNF\u2010\u03b1). This study examined the prevalence of COVID\u201019 among individuals with AS and compare it between those receiving and not receiving TNF\u2010\u03b1 inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A cross\u2010sectional study was conducted at the rheumatology clinic of Imam Khomeini Hospital in Tehran, Iran. The study included patients with AS who sought treatment at the clinic. Demographic information, laboratory and radiographic findings, and disease activity were recorded through interviews and examinations using a questionnaire.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 40 patients were studied over the course of 1 year. Among them, 31 patients were administered anti\u2010TNF\u2010\u03b1 drugs, with 15 patients (48.3%) receiving subcutaneous Altebrel (Etanercept), 3 patients (9.6%) receiving intravenous Infliximab, and 13 patients (41.9%) receiving subcutaneous Cinnora (Adalimumab). Of the total, 7 patients (17.5%) tested positive for COVID\u201019, 1 of whom was confirmed through both CT scan and polymerase chain reaction (PCR) testing, while the remaining 6 patients were confirmed only through PCR testing. All patients tested positive for COVID\u201019 were male, and 6 of them had received Altebrel. Among the 9 AS patients who did not receive TNF inhibitors, 1 patient contracted SARS\u2010CoV\u20102. The clinical symptoms experienced by these patients were mild, and hospitalization was not required. However, 1 patient who had insulin\u2010dependent type 1 diabetes and was receiving Infliximab required hospitalization. This patient exhibited more severe COVID\u201019 symptoms, including high fever, pulmonary involvement, dyspnea, and decreased oxygen saturation. No cases of COVID\u201019 were reported in the Cinnora treatment group. The use of any of the drugs did not demonstrate a significant relationship with the occurrence of COVID\u201019 in patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The use of the TNF\u2010\u03b1 inhibitors in patients with AS, may be associated with reduced hospitalization and death rate in COVID\u201019 cases.<\/jats:p><\/jats:sec>","DOI":"10.1002\/iid3.915","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T13:15:25Z","timestamp":1686748525000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prevalence and complication of COVID\u201019 in patients with ankylosing spondylitis (AS) and its relationship with TNF\u2010a inhibitors"],"prefix":"10.1002","volume":"11","author":[{"given":"Shafieh","family":"Movassaghi","sequence":"first","affiliation":[{"name":"Rheumatology Research Center, Imam Khomeini Hospital Complex Tehran University of Medical Sciences Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3210-7905","authenticated-orcid":false,"given":"SeyedAhmad","family":"SeyedAlinaghi","sequence":"additional","affiliation":[{"name":"Iranian Research Center for HIV\/AIDS, Iranian Institute for Reduction of High\u2010Risk Behaviors Tehran University of Medical Sciences Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdolrahman","family":"Rostamian","sequence":"additional","affiliation":[{"name":"Rheumatology Research Center, Imam Khomeini Hospital Complex Tehran University of Medical Sciences Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1860-9450","authenticated-orcid":false,"given":"Seyed Reza","family":"Najafizadeh","sequence":"additional","affiliation":[{"name":"Rheumatology Research Center, Imam Khomeini Hospital Complex Tehran University of Medical Sciences Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Nezhadseifi","sequence":"additional","affiliation":[{"name":"Rheumatology Research Center, Imam Khomeini Hospital Complex Tehran University of Medical Sciences Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,6,14]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X18773726"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3171\/FOC\/2008\/24\/1\/E2"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05679-7"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/le3bmj"},{"volume-title":"Firestein & Kelly's Textbook of Rheumatology","year":"2021","author":"Linden S","key":"e_1_2_10_6_1"},{"issue":"4","key":"e_1_2_10_7_1","article-title":"TNF\u2010alpha inhibitors for ankylosing spondylitis","author":"Maxwell LJ","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218946"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30211-7"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02808-2020"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1557"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.04.071"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208852"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151027"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-013-2789-x"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20575"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker087"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2007.07.006"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1051-9"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30858-8"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25685"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30309-X"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.05.032"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321760"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002809"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217871"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218580"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1240783"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2020.11.005"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2008.07.002"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00081-3"},{"key":"e_1_2_10_32_1","article-title":"A randomized placebo\u2010controlled trial of sarilumab in hospitalized patients with Covid\u201019","author":"Sivapalasingam S","year":"2021","journal-title":"MedRxiv"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0270668"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.10.007"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30317-2"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac283"}],"container-title":["Immunity, Inflammation and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iid3.915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T12:07:24Z","timestamp":1748002044000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/iid3.915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1002\/iid3.915"],"URL":"https:\/\/doi.org\/10.1002\/iid3.915","archive":["Portico"],"relation":{},"ISSN":["2050-4527","2050-4527"],"issn-type":[{"type":"print","value":"2050-4527"},{"type":"electronic","value":"2050-4527"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"2022-05-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e915"}}